Informazioni per la stampa

The extension of the Mercator Medical gloves factory in Thailand is completed.

On 9 March 2015, at our Mercator Medical factory in Thailand, the fourth and thus the last of the planned production li…

On 9 March 2015, at our Mercator Medical factory in Thailand, the fourth and thus the last of the planned production lines for latex gloves was launched. The launch of all new production lines enable the production of 110 million gloves per month.

The commissioning and test runs were successfully completed on 5 March of this year. As of 9 March 2015, the company started producing gloves on a regular basis, using all the production lines. The production capacity of the factory has reached the monthly production target of a maximum of 110 million gloves”, said Leszek Michnowski, CEO of Mercator Medical Thailand and Vice President at Mercator Medical S.A.

Wiesław Żyznowski, PhD, President of the Management Board, Mercator Medical S.A., adds: “The completed investment allows the Mercator Medical Group to take over 1% of the global share in the sale of gloves, and with time to achieve even more. The company is planning to sell 30% of the factory’s production on the US market. The rest will be sold in Europe, Africa and South America. The extension of the gloves factory will also improve the cost competitiveness of Mercator Medical (Thailand) Ltd. mainly due to the optimisation of fixed costs, chiefly in the area of administration costs.

The launch of the last line ends the part of the factory extension project initiated in 2012.

The total investment consisted of two stages:

  • The first stage involved the construction of a warehouse and office hall, which was completed in 2013.
  • The second stage required equipping the production hall and involved the purchase, installation and commissioning of four new production lines for the manufacture of gloves, and in addition the purchase and installation of a biomass-fuelled 8.0 Kcal/h power boiler, and equipping the buildings with the necessary facilities, including filter systems, ventilation pipes, pumps, latex tanks, containers for the preparation of materials for manufacture and packing station equipment.

The investment was financed with the company’s own resources, including from the issue of shares carried out in 2013 as part of the public offer preceding the company’s debut on the Warsaw Stock Exchange and from bank loans. The total cost of implementation of the investment was PLN 30 million.

To jest wyrób medyczny. Używaj go zgodnie z instrukcją używania lub etykietą.